Table 4.

Milestones for treating CML expressed as BCR-ABL1IS per NCCN42

Month>10%>1%-10%>0.1%-1%≤0.1%
3 Possible TKI resistant TKI sensitive TKI sensitive TKI sensitive 
6 TKI resistant TKI sensitive TKI sensitive TKI sensitive 
12 TKI resistant Possibly TKI resistant TKI sensitive* TKI sensitive† 
Month>10%>1%-10%>0.1%-1%≤0.1%
3 Possible TKI resistant TKI sensitive TKI sensitive TKI sensitive 
6 TKI resistant TKI sensitive TKI sensitive TKI sensitive 
12 TKI resistant Possibly TKI resistant TKI sensitive* TKI sensitive† 
*

If treatment goal is long-term survival, >0.1% to 1% optimal.

†

If treatment goal is treatment-free remission, ≤0.1% is optimal.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal